Search results for "Therapeutics"

showing 10 items of 489 documents

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

2022

Abstract Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based on ADA status, in patients from over 10 clinical trials that evaluated the immune checkpoint inhibitor atezolizumab as a single agent or as combination therapy for several types of advanced cancers. ADA can only be observed post randomization, and imbalances in baseline prognostic factors can confound the interpretation of ADA impact. We applied methodology to account for the confoundin…

Oncologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRandomizationCombination therapyDatabases FactualMEDLINERM1-950Antibodies Monoclonal HumanizedGeneral Biochemistry Genetics and Molecular BiologyArticleAtezolizumabimmune system diseasesInternal medicineNeoplasmsmedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAdverse effectImmune Checkpoint InhibitorsClinical Trials as Topicbusiness.industryGeneral NeuroscienceImmunogenicityResearchConfoundingnutritional and metabolic diseaseshemic and immune systemsGeneral MedicineArticlesAntibodies Monoclonal Humanized/immunology; Antibodies Monoclonal Humanized/pharmacokinetics; Antibodies Neutralizing/immunology; Antibodies Neutralizing/metabolism; Clinical Trials as Topic; Databases Factual; Humans; Immune Checkpoint Inhibitors/immunology; Immune Checkpoint Inhibitors/pharmacokinetics; Neoplasms/drug therapy; Safety; Treatment OutcomeAntibodies NeutralizingClinical trialenzymes and coenzymes (carbohydrates)Treatment OutcomeTherapeutics. PharmacologyPublic aspects of medicineRA1-1270SafetybusinessClinical and translational science
researchProduct

Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy

2014

Francesco Saverio Mennini,1,2 Andrea Marcellusi,1,3 Massimo Andreoni,4 Antonio Gasbarrini,5 Salvatore Salomone,6 Antonio Craxì71Centre for Economic and International Studies (CEIS) – Economic Evaluation and HTA (EEHTA) Faculty of Economics, University of Rome Tor Vergata, Rome, Italy; 2Institute of Leadership and Management in Health, Kingston University, London, UK; 3Department of Demography, University of Rome La Sapienza, Rome, Italy; 4Department of Public Health and Cell Biology, School of Medicine, University of Rome Tor Vergata, Rome, Italy; 5Gastroenterology Division, Catholic University of the Sacred Heart of Rome, School of Medicine, Rome, Italy; 6Department of…

Operations researchHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAEconomics Econometrics and Finance (miscellaneous)forecastcost of illnessmacromolecular substancesmedicine.disease_causeChronic hepatitisEnvironmental healthCost of illnessMedicineHealth policyOriginal Researchlcsh:R5-920business.industryHealth Policylcsh:RM1-950Health services researchvirus diseasesSettore SECS-S/04 - Demografianew HCV treatmentClinicoEconomics and Outcomes Researchlcsh:Therapeutics. Pharmacologychronic hepatitishepatitis Cbusinesslcsh:Medicine (General)ClinicoEconomics and Outcomes Research
researchProduct

Indicaxanthin from Opuntia ficus-indica Fruit Ameliorates Glucose Dysmetabolism and Counteracts Insulin Resistance in High-Fat-Diet-Fed Mice

2021

Obesity-related dysmetabolic conditions are amongst the most common causes of death globally. Indicaxanthin, a bioavailable betalain pigment from Opuntia ficus-indica fruit, has been demonstrated to modulate redox-dependent signalling pathways, exerting significant anti-oxidative and anti-inflammatory effects in vitro and in vivo. In light of the strict interconnections between inflammation, oxidative stress and insulin resistance (IR), a nutritionally relevant dose of indicaxanthin has been evaluated in a high-fat diet (HFD) model of obesity-related IR. To this end, biochemical and histological analysis, oxidative stress and inflammation evaluations in liver and adipose tissue were carried…

Opuntia ficus-indicaobesityPhysiologyindicaxanthin; <i>Opuntia ficus-indica</i>; phytochemicals; insulin resistance; obesity; inflammation; oxidative stress; dysmetabolismClinical BiochemistryindicaxanthinCell BiologyRM1-950phytochemicalsBiochemistryDysmetabolism<i>Opuntia ficus-indica</i>Oxidative stressinflammationinsulin resistanceTherapeutics. PharmacologyMolecular BiologyAntioxidants
researchProduct

Redox Systems, Oxidative Stress, and Antioxidant Defences in Health and Disease

2021

Reactive oxygen and nitrogen species (RONS) play a key role in the regulation of cell survival. While adequate levels of RONS are essential to sustain cell proliferation and survival, disruption of the endocellular redox state induces cell dysfunction and death. Indeed, under physiological conditions, a balance between the generation and elimination of RONS ensures the proper function of redox-sensitive signalling proteins. Conversely, alterations to the redox homeostasis may disrupt the function of key transcription factors, signaltransduction pathways and cell-death regulators. Along these lines, understanding the mechanisms underlying cellular redox homeostasis may help to develop nutrac…

Oxidative Stressn/aEditorialAntioxidant DefencesPhysiologyClinical BiochemistryCell BiologyTherapeutics. PharmacologyRM1-950Redox SystemsMolecular BiologyBiochemistryAntioxidants
researchProduct

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

2019

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1…

PBD Polo box domainMTD maximal tolerance doseCDC25 cell division cycle 25HIF-1α hypoxia-inducible factor 1 αMST microscale thermophoresisIC50 50% inhibition concentrationMFP M phase promoting factorPARP-1 poly(ADP-ribose) polymerase-10302 clinical medicineFOXO forkhead box ONec-1 necrostatin 1CDC2 cell division cycle protein 2 homologGeneral Pharmacology Toxicology and PharmaceuticsMitotic catastropheCDK cyclin-dependent kinase0303 health sciencesChemistryPolo-like kinaseMono-targeted therapyCell cycleBUBR1 budding uninhibited by benzimidazole-related 1Polo box domain030220 oncology & carcinogenesisPLK1 Polo-like kinaseNecroptosisSpindle damagePLK1IHC immunohistochemistryOriginal articleNecroptosisCell cyclePLK1APC/C anaphase-promoting complex/cyclosomePLK3ABC avidin-biotin complexPI propidium iodide03 medical and health sciencesFBS fetal bovine serumPDB Protein Data BankKd the dissociation constantKinase activity030304 developmental biologyAkt/PKB signaling pathwayCell growthlcsh:RM1-950LC3 light chain 3lcsh:Therapeutics. PharmacologyCancer researchDAPKs death-associated protein kinase3-MA 3-methyladenineDAPI 4′6-diamidino-2-phenylindoleSAC spindle assembly checkpointActa Pharmaceutica Sinica B
researchProduct

Impairment of PGC-1 Alpha Up-Regulation Enhances Nitrosative Stress in the Liver during Acute Pancreatitis in Obese Mice

2020

Acute pancreatitis is an inflammatory process of the pancreatic tissue that often leads to distant organ dysfunction. Although liver injury is uncommon in acute pancreatitis, obesity is a risk factor for the development of hepatic complications. The aim of this work was to evaluate the role of PGC-1&alpha

PGC-1&#9450301 basic medicineobesitymedicine.medical_specialtyAntioxidantacute pancreatitisPhysiologymedicine.medical_treatmentClinical BiochemistryPGC-1αAlpha (ethology)Nitrosative stressliverHepatic ComplicationBiochemistryArticle03 medical and health sciences0302 clinical medicineDownregulation and upregulationInternal medicinemedicineObesityMolecular BiologyLiver injurybusiness.industrylcsh:RM1-950Organ dysfunctionCell BiologyBiología y Biomedicina / Biologíamedicine.diseasenitrosative stressAcute pancreatitislcsh:Therapeutics. Pharmacology030104 developmental biologyEndocrinologyLiver030220 oncology & carcinogenesisPancreatitisAcute pancreatitismedicine.symptombusinessAntioxidants
researchProduct

PROTACs: The Future of Leukemia Therapeutics

2022

The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies. PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway. This review mainly focuses on the general design and functioning of PROTACs as well as current advancements in the development of PROTACs as anticancer therapies. Particular emphasis is given to PROTACs designed against various types of Leukemia/Blood malignancies.

PROTACsleukemiacanceranticancer therapeuticsCell BiologylinkerDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Optimization of the KNN Supervised Classification Algorithm as a Support Tool for the Implantation of Deep Brain Stimulators in Patients with Parkins…

2019

Deep Brain Stimulation (DBS) of the Subthalamic Nuclei (STN) is the most used surgical treatment to improve motor skills in patients with Parkinson&rsquo

Parkinson's diseaseDeep brain stimulationmicroelectrode registers-MERComputer sciencemedicine.medical_treatmentGeneral Physics and Astronomylcsh:AstrophysicsFeature selection02 engineering and technologybehavioral disciplines and activitiesArticlePharmacological treatment03 medical and health sciencesNeurologiafeature selection0302 clinical medicinedeep brain stimulation-DBSClinical supportlcsh:QB460-4660202 electrical engineering electronic engineering information engineeringmedicineIn patientlcsh:ScienceMotor skillK-nearest neighbour-KNN algorithmmedicine.diseaseBrain stimulatorslcsh:QC1-999nervous system diseasessurgical procedures operativenervous systemParkinson’s diseaselcsh:Q020201 artificial intelligence & image processingEnginyeria biomèdicatherapeuticsAlgorithmlcsh:Physics030217 neurology & neurosurgery
researchProduct

Pathological Findings in COVID-19 as a Tool to Define SARS-CoV-2 Pathogenesis. A Systematic Review

2021

Introduction: The World Health Organization declared the COVID-19 pandemic in March 2020. COVID-19 still represents a worldwide health emergency, which causesa severe disease that has led to the death of many patients. The pathophysiological mechanism of SARS-CoV-2 determining the tissue damage is not clear and autopsycan be auseful tool to improve the knowledge of this infection and, thus, it can help achieve a timely diagnosis and develop an appropriate therapy. This is an overview of the main post-mortem findings reporting data on the infection effects on several organs.Methods: A systematic literature search was conducted in the PubMed database searching for articles from 1 January to A…

Pathologymedicine.medical_specialtypathological findingThrombotic microangiopathyimmuno-thrombotic microangiopathyAutopsyDisease030204 cardiovascular system & hematologyPathogenesis03 medical and health sciencesautopsy0302 clinical medicinesystematic reviewhyperinflammatory statemedicinepathological findingsPharmacology (medical)Diffuse alveolar damagePathologicalPharmacologyLungSARS-CoV-2business.industrylcsh:RM1-950MicroangiopathyCOVID-19medicine.diseasediffuse alveolar damagelcsh:Therapeutics. Pharmacologymedicine.anatomical_structure030220 oncology & carcinogenesisSystematic ReviewbusinessFrontiers in Pharmacology
researchProduct

A Four-Year Observational Study regarding the Characteristics and Causes of the Ischemic Stroke in Young Adults: one center study report

2020

Introduction. Stroke is the second cause of mortality worldwide, after the ischemic coronary disease, and the first cause of long term-disability. Recent studies report that ischemic stroke (IS) in young patients is increasing in incidence, even though the overall stroke hospitalization rate is decreasing. Stroke in the young, working individuals significantly affects the quality of life (QoL) and also determines an important, negative economic impact by reducing the workforce. Material and method. The aim of this paper is to present the results of a 4-year observational, retrospective study on all patients between 18-49 years, who suffered from acute IS and were admitted and investigated i…

Pediatricsmedicine.medical_specialtybusiness.industrylcsh:RM1-950General Medicine030204 cardiovascular system & hematologyyoung patients03 medical and health scienceslcsh:Therapeutics. Pharmacology0302 clinical medicinedisabilityStudy reportvascular risk factorsIschemic strokeischemic strokemedicineCenter (algebra and category theory)Observational studyYoung adultbusiness030217 neurology & neurosurgerytoast classificationBalneo Research Journal
researchProduct